JACK-MA/ALIBABA
29.3.2020 07:00:09 CEST | Business Wire | Press release
The Jack Ma Foundation and the Alibaba Foundation today announced donations of essential medical supplies to seven more countries, namely Azerbaijan, Bhutan, India, Kazakhstan, Kyrgyzstan, Uzbekistan and Vietnam.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200328005024/en/
Collectively, these seven countries will receive a total of 1.7 million face masks, 165,000 test kits as well as protective clothing and medical equipment such as ventilators and forehead thermometers. With this announcement, the two Foundations have now donated essential medical supplies to 23 Asian countries totalling 7.4 million masks; 485,000 test kits; 100,000 sets of protective clothing along with other medical equipment.
The first batch of medical supplies for India arrived in Delhi last night and were received by the Indian Red Cross Society. Similar to the arrangement with the Italian Red Cross Society, the Indian charity will facilitate the distribution of these supplies in the country. The donations are expected to reach other countries in the coming days.
Mr. Neel Kamal Singh, Deputy Secretary, Indian Red Cross Society took receipt of the donations from Mr. Vivek Sehgal, Manager, Alibaba Cloud India, acting on behalf of the Jack Ma Foundation and the Alibaba Foundation. Ms. Ma Jia, Deputy Chief of Mission of the Embassy of China in India, was also present to show the embassy’s support towards this humanitarian initiative.
“Government of India has taken extensive steps to manage the COVID-19 situation. To supplement the efforts of government, Indian Red Cross has mobilised first tranche of supplies consisting of facemasks, protective body suits and essential medical equipment. This consignment, which was received yesterday, has been donated by Jack Ma Foundation and Alibaba Foundation. Indian Red Cross appreciates their magnanimity at this difficult juncture,” said Mr. R.K Jain, IAS (Rtd), Secretary General, Indian Red Cross .
“We are one with the global community in the intense battle to protect all families against Covid-19. We are committed to doing everything we can to make a difference, most importantly by sourcing these supplies and overcoming logistical challenges to get the medical supplies to where they are needed as fast as we can,” said the Jack Ma Foundation .
These donations are among a number of aid initiatives from the Alibaba Foundation and Jack Ma Foundation to support the areas of the world affected by the Covid-19 crisis, sourcing and delivering various types of medical supplies to countries across Asia, North America, Latin America, Europe and Africa. The donation by the two foundations to Vietnam is in addition to the recent donation by Lazada Group, Alibaba Group’s local e-commerce business unit in Southeast Asia.
More initiatives and donations may be announced in the coming days and weeks.
The Jack Ma Foundation and the Alibaba Foundation also supported the publication of a handbook with key lessons and experience from doctors, healthcare workers, and hospital administrators at the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), who were on the frontline of COVID-19 treatment in China and crucial to slowing its spread. The handbook is available for global medical health professionals at https://covid-19.alibabacloud.com/ .
Follow @JackMa and @foundation_ma on Twitter for the latest efforts of Jack Ma Foundation and Alibaba Foundation to support the global fight against COVID-19.
About Jack Ma Foundation
Established by Jack Ma, the founder of Alibaba Group, the Jack Ma Foundation was founded on 15 December 2014 and has been focusing on education, entrepreneurship, women’s leadership, and the environment. The Foundation aspires to be a reliable, participative, and sustainable philanthropic organization. The Jack Ma Foundation has so far supported projects worldwide including the Jack Ma Rural Education Program, the Africa Netpreneur Prize Initiative, the Ma & Morley Scholarship Program, and Jordan's Queen Rania Foundation. Additionally, the Foundation has also funded a number of projects in its priority areas. The Jack Ma Foundation is committed to empowering rural educators, entrepreneurs, rural children, young start-ups, and women to equip them for the future and to help build a happier, healthier, more sustainable and more inclusive society.
About Alibaba Foundation
The Alibaba Foundation, established in December 2011, aims to create a culture that encourages people to get involved in philanthropy, make it sustainable and genuinely contribute to civil society and nature. Its key funding aspects include water protection, environmental awareness promotion and development of green organizations. Alibaba Group is committed to devoting a percentage of its annual income to the Alibaba Foundation to ensure stable long-term funding that will allow for timely response in the event of natural disasters or expansion of philanthropic projects.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200328005024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom